We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

By LabMedica International staff writers
Posted on 22 May 2023
Print article
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Preeclampsia, a critical complication during pregnancy, is a life-threatening hypertension condition that can arise during pregnancy and continue into the postpartum period. As the chief cause of maternal and fetal deaths and health issues globally, preeclampsia has seen a marked increase in incidence rates within the United States over the past ten years. Now, the first and only immunoassays for the risk assessment and clinical management of preeclampsia have received breakthrough designation and clearance.

Thermo Fisher Scientific (Waltham, MA, USA) has received the U.S. Food and Drug Administration (FDA) clearance for its B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers. These groundbreaking assays are intended for use in conjunction with other lab tests and clinical evaluations to assist in assessing the risk of pregnant women admitted for hypertensive pregnancy disorders, and determining their likelihood of developing severe preeclampsia features within the subsequent two weeks.

Testing of the blood-based biomarkers, B·R·A·H·M·S sFlt-1 KRYPTOR and B·R·A·H·M·S PlGF plus KRYPTOR, aids in identifying the onset of severe preeclampsia, as corroborated by the PRAECIS study. The study encompassed 18 U.S. hospitals and over 700 pregnant women nationwide. Women with a positive test result, determined by the risk stratification ratio of the two assays (sFlt-1/PlGF ratio ≥ 40), could benefit from increased monitoring and expedited care before the emergence of severe features. These novel assays have been designed for operation on the Thermo Scientific B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer. Utilizing TRACE technology, based on Nobel Prize-winning chemistry, the analyzer can yield results in under 30 minutes.

“Thermo Fisher is committed to advancing diagnostic solutions for reproductive health as part of our broader Mission to enable our customers to make the world healthier, cleaner, and safer,” said Alan Sachs, chief medical officer at Thermo Fisher Scientific. “Today’s clearance of these breakthrough biomarkers will have a significant impact on prognosis and treatment for thousands of women at risk for preeclampsia every year in the U.S.”

Related Links:
Thermo Fisher Scientific 

Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
New
Rapid Test Analyzer
RapiRead CUBE Reader
New
Silver Supplier
HSV1+2 / VZV Test
Savvygen HSV1+2 / VZV

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.